Revenue
2022
2023
2024
2025
Artiva Biotherapeutics, Inc. (ARTV)
Price$11.18Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $251,000 | $32.9M | $4.9M |
| Research & development | $69.5M | $50.3M | $50.3M | $44.0M |
| Operating expenses | $89.8M | $67.5M | $64.2M | $64.8M |
| Operating income | −$89.8M | −$67.3M | −$30.7M | −$59.8M |
| Operating margin | — | −26,805.58% | −93.16% | −1,213.32% |
| EBITDA | −$87.2M | −$64.9M | −$28.4M | −$58.7M |
| EBITDA margin | — | −25,837.05% | −86.28% | −1,189.84% |
| Net income | −$83.9M | −$65.4M | −$28.7M | −$61.0M |
| Net profit margin | — | −26,045.02% | −87.23% | −1,236.58% |
| Basic EPSper basic share | -$3.43 | -$5.81 | -$35.78 | -$6.51 |
| Diluted EPSper diluted share | -$3.43 | -$5.81 | -$35.78 | -$6.51 |
Owners
Reported shareholders
36.80%of listed shares
RA CAPITAL MANAGEMENT, L.P.17.96M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 36.80%17.96M shares |
GC Corp. / GC Cell Corp | ≈12.30%6M shares |
Huh Yong-Jun | ≈9.36%4.57M shares |
VIKING GLOBAL INVESTORS LP | 5.34%2.6M shares |
Blackstone Inc. | 4.93%2.4M shares |
5AM Partners VI, LLC / 5AM Opportunities II (GP), LLC / Schwab Andrew J. / PARMAR KUSH / 5AM Ventures VI, L.P. / 5AM Opportunities II, L.P. | ≈4.82%2.35M shares |
5AM Venture Management, LLC | 4.82%2.35M shares |
Venrock Adviser, LLC | 4.19%2.04M shares |
FRANKLIN RESOURCES INC | 4.09%2M shares |
VENBIO GLOBAL STRATEGIC GP III, LTD / Adelman Robert J / venBio Global Strategic Fund III, L.P. / GOODMAN COREY S / VENBIO GLOBAL STRATEGIC GP III, L.P. | ≈3.97%1.94M shares |
Caligan Partners LP | 3.56%1.74M shares |
Aslan Fred | ≈3.15%1.54M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.01%981.82K shares |
SAMSARA BIOCAPITAL, LLC | 1.96%954.86K shares |
Blue Owl Capital Holdings LP | 1.79%874.54K shares |
Propel Bio Management, LLC | 1.43%696.44K shares |
BlackRock, Inc. | 1.42%694.73K shares |
CITADEL ADVISORS LLC | 1.25%609.38K shares |
Nantahala Capital Management, LLC | 1.23%600K shares |
SILVERARC CAPITAL MANAGEMENT, LLC | 1.08%525K shares |
Percentages use 48.79M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +5Director,TenPercentOwner | BuyCommon Stock · indirect | 1.9K | $8.98 | $16.8K | 16.80M |
| Jun 25, 2026Form 4 | RA CAPITAL MANAGEMENT, L.P. +5Director,TenPercentOwner | BuyCommon Stock · indirect | 31.0K | $8.88 | $275.3K | 16.79M |
| Jun 16, 2026Form 4 | Kolchinsky Peter +5Director,TenPercentOwner | BuyCommon Stock · indirect | 124.9K | $8.89 | $1.11M | 16.76M |
| Jun 15, 2026Form 4 | Kolchinsky Peter +5Director,TenPercentOwner | BuyCommon Stock · indirect | 15.4K | $8.99 | $138.6K | 16.64M |
| Jun 12, 2026Form 4 | Kolchinsky Peter +5Director,TenPercentOwner | BuyCommon Stock · indirect | 391.0K | $8.57 | $3.35M | 16.62M |